全文获取类型
收费全文 | 3346篇 |
免费 | 227篇 |
国内免费 | 191篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 41篇 |
妇产科学 | 35篇 |
基础医学 | 440篇 |
口腔科学 | 74篇 |
临床医学 | 322篇 |
内科学 | 675篇 |
皮肤病学 | 178篇 |
神经病学 | 259篇 |
特种医学 | 86篇 |
外科学 | 381篇 |
综合类 | 165篇 |
预防医学 | 229篇 |
眼科学 | 71篇 |
药学 | 392篇 |
1篇 | |
中国医学 | 49篇 |
肿瘤学 | 353篇 |
出版年
2023年 | 14篇 |
2022年 | 69篇 |
2021年 | 103篇 |
2020年 | 52篇 |
2019年 | 69篇 |
2018年 | 85篇 |
2017年 | 86篇 |
2016年 | 102篇 |
2015年 | 112篇 |
2014年 | 155篇 |
2013年 | 165篇 |
2012年 | 248篇 |
2011年 | 223篇 |
2010年 | 134篇 |
2009年 | 109篇 |
2008年 | 176篇 |
2007年 | 254篇 |
2006年 | 146篇 |
2005年 | 200篇 |
2004年 | 151篇 |
2003年 | 125篇 |
2002年 | 119篇 |
2001年 | 104篇 |
2000年 | 79篇 |
1999年 | 68篇 |
1998年 | 31篇 |
1997年 | 32篇 |
1996年 | 24篇 |
1995年 | 20篇 |
1994年 | 23篇 |
1993年 | 21篇 |
1992年 | 52篇 |
1991年 | 33篇 |
1990年 | 27篇 |
1989年 | 22篇 |
1988年 | 37篇 |
1987年 | 27篇 |
1986年 | 19篇 |
1985年 | 15篇 |
1983年 | 11篇 |
1981年 | 10篇 |
1980年 | 10篇 |
1977年 | 12篇 |
1976年 | 15篇 |
1973年 | 10篇 |
1972年 | 22篇 |
1970年 | 16篇 |
1969年 | 10篇 |
1968年 | 11篇 |
1967年 | 11篇 |
排序方式: 共有3764条查询结果,搜索用时 15 毫秒
1.
Anders Elm Pedersen Esben Gjerløff Wedebye Schmidt Jesper Freddie Sørensen Carsten Faber Boye Schnack Nielsen Kim Holmstrøm Silje Haukali Omland Peter Tougaard Søren Skov Bo Bang 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2015,123(7):547-555
TL1A is a TNF‐like cytokine which has been shown to co‐stimulate TH1 and TH17 responses during chronic inflammation. The expression of this novel cytokine has been investigated in inflammatory disorders like rheumatoid arthritis and inflammatory bowel disease, but little is known about expression and induction in psoriasis. Indeed, the pathogenesis in psoriasis is still not fully understood and it is speculated that cytokines other than TNF‐α are important in subsets of patients. Also, for patients with severe disease that are treated with systemic anti‐TNF‐α blockade, novel candidates to be used as disease and response biomarkers are of high interest. Here, we demonstrate TL1A expression in biopsies from psoriatic lesions. Also, we investigated spontaneous and induced TL1A secretion from PBMCs and blood levels from a cohort of psoriasis patients. Here, increased spontaneous secretion from PBMCs was observed as compared to healthy controls and a small subset of patients had highly elevated TL1A in the blood. Interestingly, activation of PBMCs with various cytokines showed a decreased sensitivity for TL1A activation in psoriasis patients compared to healthy controls.TL1A levels in blood and biopsies could not be correlated with disease activity with this patient cohort. Thus, additional large‐scale studies are warranted to investigate TL1A as a biomarker. 相似文献
2.
Frank Lindseth Thomas Lang? Jon Bang Toril A Nagelhus Hernes 《Computer aided surgery》2002,7(4):197-222
3.
4.
5.
赛赓啶对 KBV200细胞多药抗性的逆转作用 总被引:3,自引:0,他引:3
研究赛赓啶对KBV200细胞多药抗性的逆转作用及逆转机制。在KBV200细胞,采用MTT法,测出赛赓啶对长春新碱、阿霉素和鬼臼乙叉甙耐药的逆转系数分别为5.5,2.0和1.9,而对5-氟尿嘧啶、美法仑的细胞毒性作用无明显影响,表明赛赓啶为多药抗性逆转剂。荧光分光光度法测定表明,赛赓啶可使KBV200细胞内阿霉素蓄积量增加。流式细胞荧光测定显示赛赓啶可增加罗丹明123的蓄积并减慢其外排。免疫细胞化学及狭缝杂交表明赛赓啶不影响KBV200细胞的P-糖蛋白染色深度和 mdr1 RNA 表达水平。以上结果提示赛赓啶的多药抗性逆转机制是抑制P-糖蛋白泵的功能。 相似文献
6.
7.
Palmar advancement flap with V-Y closure for thumb tip injuries 总被引:1,自引:0,他引:1
Hwang-hyun Bang MD Tadao Kojima MD Hiroyuki Hayashi MD 《The Journal of hand surgery》1992,17(5):933-934
The palmar advancement flap with V-Y closure was used in two patients with thumb tip injuries. This technique allows more distal advancement of the flap than does a conventional palmar advancement flap and does not require skin graft coverage. 相似文献
8.
Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome. 总被引:5,自引:0,他引:5
BACKGROUND. Deposition of fibrin in glomeruli and renal failure are characteristic features of the hemolytic uremic syndrome. An inhibitor of glomerular fibrinolysis has been detected in plasma from children with this disorder. In this study, we define the inhibitor and show that its plasma level is correlated with the outcome of the disease. METHODS AND RESULTS. Plasminogen-activator inhibitor type 1 (PAI-1) in plasma was measured with an assay employing a specific monoclonal antibody in 40 consecutive children hospitalized with the hemolytic uremic syndrome: 12 who recovered adequate renal function (serum creatinine, less than or equal to 2.0 mg per deciliter [177 mumol per liter]) without dialysis, 23 who recovered adequate renal function after peritoneal dialysis, and 5 who did not recover adequate renal function after undergoing dialysis. At presentation, plasma PAI-1 levels were higher in the patients with the hemolytic uremic syndrome than in nine children with other forms of acute renal failure. That the inhibitor was PAI-1 was indicated by the fact that it was a potent inhibitor of tissue plasminogen activator, was acid-resistant, and was not inhibited by denaturation (all unique traits of PAI-1) and that it was neutralized by an antibody specific for PAI-1. Multivariate discriminant-function analysis revealed that the duration of elevated PAI-1 activity was strongly correlated with the outcome of the disease (P less than 0.001). Peritoneal dialysis reduced plasma PAI-1 levels dramatically. CONCLUSIONS. Our studies suggest that PAI-1 is the circulating inhibitor of fibrinolysis in the hemolytic uremic syndrome. Normalization of plasma PAI-1 levels (e.g., by peritoneal dialysis) is correlated with improvement in renal function. However, the possibility that increased plasma levels of PAI-1 are either causes or effects of the hemolytic uremic syndrome is not unequivocally established by these studies. 相似文献
9.
Bum Soon Choi Mi Jung Shin Suk Joon Shin Young Soo Kim Yeong Jin Choi Yong-Soo Kim In Sung Moon Suk Young Kim Yong Bok Koh Byung Kee Bang Chul Woo Yang 《American journal of transplantation》2005,5(6):1354-1360
We report here our 10-year experience of a biopsy performed at day 14 after transplantation in 304 patients with stable graft function. The factors that may have influenced subclinical rejection were analyzed according to histology. The incidence of subclinical rejection was 13.2%. Addition of mycophenolate mofetile (MMF) as a primary immunosuppressant significantly decreased the incidence of subclinical rejection compared with patients without such treatment (odds ratio, 0.23; p < 0.05). On the other hand, HLA-DR antigen mismatch (odds ratio, 2.39) and unrelated donor (odds ratio, 2.10) were also significantly associated with decreased subclinical rejection (p < 0.05). The incidence of acute rejection in patients with normal findings was lower than in those with borderline changes or subclinical rejection (0.23 +/- 0.05 vs. 0.48 +/- 0.07 and 0.60 +/- 0.11, respectively; p < 0.05). The graft survival rates in patients with subclinical rejection were lower than in patients with normal or borderline changes at 1 (88.4% vs. 97.9% and 99.1%; p < 0.05), 5 (77.8% vs. 96.2% and 95.9%; p < 0.05) and 10 (62.3% vs. 96.2% and 93.7%; p < 0.05) years. Thus, a protocol biopsy performed on day 14 after transplantation is useful for predicting graft survival. Triple therapy including MMF, related donor and HLA-DR antigen match are important factors for reducing subclinical rejection in living-donor renal transplantation. 相似文献
10.